0001104659-24-084629.txt : 20240801 0001104659-24-084629.hdr.sgml : 20240801 20240801072921 ACCESSION NUMBER: 0001104659-24-084629 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240801 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240801 DATE AS OF CHANGE: 20240801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 241164277 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 tm2420612d1_8k.htm FORM 8-K
false 0001597264 0001597264 2024-08-01 2024-08-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): August 1, 2024

 

 

 

Blueprint Medicines Corporation

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37359   26-3632015

(State or other jurisdiction

of incorporation)

   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

45 Sidney Street

Cambridge, Massachusetts

   02139
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (617) 374-7580

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class Trading symbol(s) Name of each exchange on which
registered
Common stock, par value $0.001 per share BPMC Nasdaq Global Select Market

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 1, 2024, Blueprint Medicines Corporation (the “Company”) announced its financial results for the quarter ended June 30, 2024 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01  Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:

 

Exhibit No.    Description 
99.1   Press release issued by Blueprint Medicines Corporation on August 1, 2024
104    Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101) 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BLUEPRINT MEDICINES CORPORATION
   
Date: August 1, 2024 By:

/s/ Kathryn Haviland

    Kathryn Haviland
    Chief Executive Officer

 

 

 

 EX-99.1 2 tm2420612d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

 

-- Achieved $114.1 million in AYVAKIT net product revenues in the second quarter 2024 --

 

-- Raising AYVAKIT net product revenue guidance to $435 million to $450 million for 2024 --

 

-- Initiated Phase 1 healthy volunteer trial of wild-type KIT inhibitor BLU-808 --

 

CAMBRIDGE, Mass., August 1, 2024 – Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the second quarter ended June 30, 2024, and provided updated financial guidance.

 

“This quarter marks a milestone, as we celebrate one full year since the U.S. approval of AYVAKIT for indolent systemic mastocytosis. We have delivered yet another very strong quarter of revenue as we continue to build this new rare disease market, and we are well on path to achieve more than $2 billion in potential peak sales. In addition, we have invested in our next pillars of growth, building on AYVAKIT as the cornerstone of a mast cell disease franchise. Our wild-type KIT inhibitor BLU-808 has entered a Phase 1 healthy volunteer study and we expect to initiate the registration-enabling HARBOR Part 2 study of our next-generation KIT D816V inhibitor elenestinib in indolent systemic mastocytosis later this year,” said Kate Haviland, Chief Executive Officer of Blueprint Medicines. “With a significant and growing revenue base from AYVAKIT, a next wave of therapies in our pipeline that we believe can address even larger scale patient opportunities, and a financial profile anchored in sustainable topline revenue growth that enables us the flexibility to invest in the next wave of innovation, we are building Blueprint Medicines for long term value.”

 

Second Quarter 2024 Highlights and Recent Progress

 

Mast cell disorders

 

·Achieved AYVAKIT net product revenues of $114.1 million for second quarter of 2024, representing more than 185 percent growth year-over-year.

·Achieved clearance of an Investigational New Drug application for BLU-808 by the U.S. Food and Drug Administration and initiated the healthy volunteer study. BLU-808 is a highly selective and potent investigational oral wild-type KIT inhibitor with best-in-class potential, for chronic urticaria and other mast cell disorders.

·Presented multiple datasets highlighting the long-term safety and durable clinical outcomes of AYVAKIT®/AYVAKYT® (avapritinib) across the spectrum of systemic mastocytosis (SM) at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) and European Hematology Association (EHA) conferences. Read the presentations here.

 

Cell cycle inhibition

 

·Presented data from the Phase 1 VELA study of BLU-222, an oral, potent and selective CDK2 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) meeting. This is the first positive combination safety data with signals of early clinical activity for a CDK2 inhibitor in combination with an approved CDK4/6 inhibitor, ribociclib, and fulvestrant, in patients with HR+/HER2- breast cancer. Read the presentation here.

 

2024 Financial Guidance

 

Blueprint Medicines now anticipates approximately $435 million to $450 million in global AYVAKIT net product revenues for all approved indications in 2024, an increase from the previous range of $390 million to $410 million. The company continues to expect that full-year operating expenses and cash burn will decline in 2024 as compared to 2023, and that its existing cash, cash equivalents and investments, together with anticipated product revenues, will enable the company to maintain a durable capital position to achieve a self-sustainable financial profile.

 

 

 

 

Key Upcoming Milestones

 

The company plans to achieve the following remaining milestones in the second half of 2024:

 

Mast cell disorders

·Initiate registration-enabling Part 2 of the HARBOR trial in indolent systemic mastocytosis (ISM).

 

Cell cycle inhibition

·Continue strategic business development discussions.

·Complete Phase 1 combination dose escalation for BLU-222 by end of year to inform registration plans.

 

Second Quarter 2024 Results

 

·Revenues: Revenues were $138.2 million for the second quarter of 2024, including $114.1 million of net product revenues from sales of AYVAKIT/AYVAKYT and $24.0 million in collaboration, license and other revenues. Revenues were $57.6 million in the second quarter of 2023, including $39.9 million of net product revenues from sales of AYVAKIT/AYVAKYT and $17.7 million in collaboration, license and other revenues.

·Cost of Sales: Cost of sales was $7.6 million for the second quarter of 2024, as compared to $2.3 million for the second quarter of 2023. The increase was primarily due to the sale of GAVRETO® (pralsetinib) product to Rigel.

·R&D Expenses: Research and development expenses were $84.3 million for the second quarter of 2024, as compared to $110.1 million for the second quarter of 2023. This decrease was primarily due to operational efficiency across our portfolio as we execute across our top priority programs and the timing of manufacturing of clinical trial materials. Research and development expenses included $12.3 million in stock-based compensation expenses for the second quarter of 2024.

·SG&A Expenses: Selling, general and administrative expenses were $89.3 million for the second quarter of 2024, as compared to $71.9 million for the second quarter of 2023. This increase was primarily due to an increase in activities supporting the commercialization of AYVAKIT/AYVAKYT. Selling, general, and administrative expenses included $15.7 million in stock-based compensation expenses for the second quarter of 2024.

·Net Loss: Net loss was $50.0 million for the second quarter of 2024, as compared to a net loss of $132.8 million for the second quarter of 2023.

·Cash Position: As of June 30, 2024, cash, cash equivalents and investments were $868.5 million, as compared to $767.2 million as of December 31, 2023. This increase was primarily due to taking an additional draw under our 2022 debt facility with Sixth Street Partners. Blueprint Medicine’s cash and investments provide a durable capital position which, together with anticipated product revenues, the company believes will enable it to reach a self-sustainable financial profile.

 

Conference Call Information

 

Blueprint Medicines will host a live conference call and webcast at 8:00 a.m. ET today to discuss second quarter 2024 financial results and recent business activities. The conference call may be accessed by dialing 833-470-1428 (domestic) or 404-975-4839 (international), and referring to conference ID 299779. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

 

 

 

 

Upcoming Investor Conferences

 

Blueprint Medicines will participate in two upcoming investor conferences:

·Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 1:50 p.m. ET.

·2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 11:00 a.m. ET.

 

A live webcast of the fireside discussions will be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com. A replay of the webcasts will be archived on the Blueprint Medicines website for 30 days following the events.

 

About Blueprint Medicines

 

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines’ operations, including its expectations regarding growth and product revenue in 2024; statements regarding our current or future approved drugs and drug candidates and operations, including AYVAKIT’s potential to achieve more than $2 billion in peak sales; plans to initiate registration-enabling Part 2 of the HARBOR trial in ISM, complete Phase 1 combination dose escalation for BLU-222 to inform registration plans and continue strategic business development discussions all in the second half of 2024; plans to advance our portfolio by targeting additional allergic-inflammatory diseases driven by mast cells; expectations related to the markets for our current or future approved drugs and drug candidates, including expectations regarding the size or scale of patient opportunities that our future approved drugs and drug candidates could address; the potential benefits of any of our current or future approved drugs or drug candidates in treating patients; statements related to our liquidity and capital position, including expectations that our cash, cash equivalents and investments will provide a durable capital position which, together with anticipated product revenues, will enable us to reach a self-sustainable financial profile; and our financial performance, strategy, goals and anticipated milestones, business plans and focus, including expectations regarding our revenue ramp and continued decline in operating expenses and cash burn. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: the risk that the marketing and sale of AYVAKIT/ AYVAKYT or any future approved drugs may be unsuccessful or less successful than anticipated, or that AYVAKIT/ AYVAKYT may not gain market acceptance by physicians, patients, third-party payors and others in the medical community; the risk that the market opportunities for AYVAKIT/ AYVAKYT or our drug candidates are smaller than we estimate or that any approval we obtain may be based on a narrower definition of the patient population that we anticipate; the risk of delay of any current or planned clinical trials or the development of Blueprint Medicines’ current or future drug candidates; risks related to Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; preclinical and clinical results for Blueprint Medicines' drug candidates may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates may be delayed or slower than anticipated; actions of regulatory agencies may affect our approved drugs or our current or future drug candidates, including affecting the initiation, timing and progress of clinical trials; risks related to Blueprint Medicines' ability to obtain, maintain and enforce patent and other intellectual property protection for its products and current or future drug candidates it is developing; the success of Blueprint Medicines' current and future collaborations, financing arrangements, partnerships or licensing and other arrangements; risks related to our liquidity and financial position, including the risk that we may be unable to generate sufficient future product revenues to achieve and maintain a self-sustainable financial profile; and the accuracy of our estimates of revenues, expenses and capital requirements. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

 

 

 

 

Trademarks

 

Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation. GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation outside of the United States.

 

Blueprint Medicines Corporation

Selected Condensed Consolidated Balance Sheet Data

(in thousands)

(unaudited)

 

   June 30,   December 31, 
   2024   2023 
Cash, cash equivalents and investments  $868,471   $767,171 
Working capital (1)   659,741    593,470 
Total assets   1,203,560    1,049,250 
Deferred revenue (2)   11,789    5,604 
Liability related to the sale of future royalties and revenues (2)   265,533    441,625 
Term loan (2)   386,914    238,813 
Total liabilities   883,319    918,641 
Total stockholders’ equity   320,241    130,609 

 

  (1)Blueprint Medicines defines working capital as current assets less current liabilities.

  (2)Includes both current and long-term portions of the balance.

 

 

 

 

Blueprint Medicines Corporation

Condensed Consolidated Statements of Operations Data

(in thousands, except per share data)

(unaudited)

 

   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2024   2023   2024   2023 
Revenues:                    
Product revenue, net  $114,115   $39,876   $206,641   $78,945 
Collaboration and license and other revenue   24,042    17,694    27,632    41,912 
Total revenues   138,157    57,570    234,273    120,857 
Cost and operating expenses:                    
Cost of sales   7,593    2,323    10,785    5,498 
Collaboration loss sharing   —    1,234    —    2,530 
Research and development   84,270    110,063    172,461    222,135 
Selling, general and administrative   89,339    71,931    172,896    142,882 
Total cost and operating expenses   181,202    185,551    356,142    373,045 
Other income (expense):                    
Interest expense, net   (6,864)   (3,996)   (12,760)   (9,815)
Other income (expense), net   (1)   (626)   376    359 
Debt extinguishment gain   18    —    173,676    — 
Total other income (expense), net   (6,847)   (4,622)   161,292    (9,456)
Income (loss) before income taxes   (49,892)   (132,603)   39,423    (261,644)
Income tax expense   102    190    282    710 
Net Income (loss)  $(49,994)  $(132,793)  $39,141   $(262,354)
Net income (loss) per share — basic  $(0.80)  $(2.19)  $0.63   $(4.35)
Net income (loss) per share — diluted  $(0.80)  $(2.19)  $0.61   $(4.35)
Weighted-average number of common shares used in net income (loss) per share — basic   62,854    60,516    62,217    60,322 
Weighted-average number of common shares used in net income (loss) per share —diluted   62,854    60,516    64,612    60,322 

 

Media Contact

 

Andrew Law

617-844-8205

media@blueprintmedicines.com

 

Investor Contact

 

Jenna Cohen

857-209-3147

ir@blueprintmedicines.com

 

 

 

 EX-101.SCH 3 bpmc-20240801.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bpmc-20240801_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 bpmc-20240801_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Cover
Aug. 01, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 01, 2024
Entity File Number 001-37359
Entity Registrant Name Blueprint Medicines Corporation
Entity Central Index Key 0001597264
Entity Tax Identification Number 26-3632015
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 45 Sidney Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code 617
Local Phone Number 374-7580
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol BPMC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://blueprintmedicines.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bpmc-20240801.xsd bpmc-20240801_lab.xml bpmc-20240801_pre.xml tm2420612d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2420612d1_8k.htm": { "nsprefix": "BPMC", "nsuri": "http://blueprintmedicines.com/20240801", "dts": { "schema": { "local": [ "bpmc-20240801.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "bpmc-20240801_lab.xml" ] }, "presentationLink": { "local": [ "bpmc-20240801_pre.xml" ] }, "inline": { "local": [ "tm2420612d1_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://blueprintmedicines.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-08-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2420612d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-08-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2420612d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-084629-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-084629-xbrl.zip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end XML 16 tm2420612d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001597264 2024-08-01 2024-08-01 iso4217:USD shares iso4217:USD shares false 0001597264 8-K 2024-08-01 Blueprint Medicines Corporation DE 001-37359 26-3632015 45 Sidney Street Cambridge MA 02139 617 374-7580 false false false false false Common stock, par value $0.001 per share BPMC NASDAQ